Background: Genetic analyses have identified BRAF V600E mutations in a subset of ovarian carcinomas. The aim of this study was to investigate the expression of BRAF V600E aberrant protein using a novel mutation-specific antibody in epithelial ovarian tumors.
V -RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine kinase involved in the mitogen-activated protein kinase (MAPK) pathway. Activating mutations of BRAF, most commonly (> 95%) of the V600E type, are found in a wide range of human tumors including melanoma, papillary thyroid cancer, hairy cell leukemia, and others. 1 The BRAF V600E mutation causes a substitution of valine by glutamic acid in the activating segment of the kinase domain of BRAF, thus leading to constitutive kinase activity. 2 Activation of downstream targets leads to increased proliferative and metastatic tumor activity, and several specific inhibitors of BRAF V600E-mutated protein have been developed. Most notably, the oral BRAF inhibitor vemurafenib showed remarkable increases of overall and progressionfree survival in BRAF V600E-mutated metastatic melanoma and recently received approval by the US Food and Drug Administration. 3, 4 In epithelial ovarian tumors, genetic studies have identified BRAF mutations including V600E in up to 30% of serous tumors with low malignant potential (LMP) and low-grade serous carcinomas, whereas they are rare in high-grade serous carcinomas. [5] [6] [7] [8] The Catalogue of Somatic Mutations in Cancer database specifies BRAF mutation rates of 4% for ovarian carcinomas (56 mutations in 1253 samples) and 34% for LMP tumors (172 mutations in 508 samples). Among all listed BRAF alterations, mutations of the V600E type constitute 39/53 (74%) in ovarian carcinoma and 169/172 (94%) in ovarian tumors of LMP.
We have recently introduced the mutation-specific monoclonal antibody VE1, which allows immunohistochemical detection of V600E-mutated BRAF protein with high sensitivity and specificity in formalin-fixed and paraffin-embedded (FFPE) tumor tissue samples. 9, 10 Furthermore, we showed that BRAF V600E mutant protein is generally expressed homogenously throughout the tumor tissue, although to date most analyzed samples represented metastatic lesions. Here, we utilized antibody VE1 to investigate BRAF V600E protein expression in a series of human epithelial ovarian tumors.
MATERIALS AND METHODS

Patients and Materials
Ninety-eight FFPE cases of epithelial ovarian carcinoma, FIGO stages I to IV were retrieved from our archive. Before therapy, patients were evaluated by clinical and ultrasound examination, chest x-ray, and computerized tomography or magnetic resonance imaging. Extensive surgery with total abdominal hysterectomy, bilateral salpingo-oopherectomy, pelvic lymph node dissection, and omentectomy, was performed in all patients. Surgery was followed by 6 cycles of a platinum/taxol containing adjuvant chemotherapy, except in patients with grade 1, stage IA tumors.
Response to chemotherapy was rated as described previously. 11 In brief: "No evidence of disease" was defined as the complete disappearance of all evidence of disease for at least 4 weeks, confirmed by physical examination, computed tomographic scan, and ultrasound. "Partial response" was defined as a Z50% decrease in the sum of the products of the diameters of measurable lesions for at last 4 weeks. "Stable disease" was defined as a steady state of response less than a partial response or progression <25% of at least 4 weeks duration. "Progressive disease" was defined as an increase of Z25% in the size of the measurable lesion or the appearance of a new lesion within 2 months after beginning of chemotherapy. Patients were followed at 3-month intervals.
In addition, 44 ovarian tumors of LMP (so called "borderline tumors") stage IA (limited to 1 ovary without rupture of the ovarian capsule) were investigated. In 1 patient an LMP tumor in 1 ovary and a serous carcinoma in the other was investigated (included in the above numbers).
Methods Immunohistochemistry
We performed anti-BRAF V600E immunostaining using the novel monoclonal mouse antibody VE1 (antibody kindly supplied by A.v.D.) as described previously on 3-mm-thick tissue sections from FFPE tumor tissue blocks. 9,10 Scoring of immunostaining results was performed by 2 observers (M.P. and P.B.) blinded to all clinical, histopathologic and genetic data. Immunoreaction was scored positive, when viable tumor cells showed a nonambiguous cytoplasmic staining for VE1. A faint diffuse staining, any type of isolated nuclear staining, weak staining of single interspersed cells, or staining of monocytes/macrophages was scored negative.
Data on HIF-1a, p21, p53, p21, and bcl-2 expression and microvessel density (MVD) were available from a previous study for all cases. 11 Expression of HIF-1a, p21, and bcl-2 was scored as "negative," "weak," "moderate," and "strong," expression of p53 as "positive" or "negative" as described previously. 11 MVD was assessed by counting the field of view with the highest numbers of microvessels using a magnification of Â 200.
Polymerase Chain Reaction Amplification and Direct Sequencing
In 15 selected cases (all immunopositive or equivocal tumors and 6 negative control cases), we performed direct sequencing of BRAF exon 15 mutations for validation of immunostaining results. In all 15 cases, gene sequencing was performed at the Department of Pathology (Medical University of Vienna) as described previously using capillary sequencing and mutations were identified using SeqScape (Applied Biosystems). 12 In 2 LMP cases with low tumor cell content macrodissection was applied to separate tumor cells from non-neoplastic tissue parts and a second round of gene sequencing using the Quiagen V600 kit (QIAGEN GmbH, Du¨sseldorf, Germany) was performed. Two tissue blocks derived from a single patient (1 LMP and 1 contralateral serous carcinoma) showed heterogenous VE1 immunostaining. These 2 blocks were subjected to a second round of BRAF exon 15 sequencing after macrodissection using the Qiagen V600 kit in Vienna and a third round of sequencing (in one of the blocks with prior macrodissection of immunostained vs. nonimmunostained tissue parts) at the Department of Neuropathology (University of Heidelberg) as described previously. 9 Statistical Analysis w 2 test and Mann-Whitney test were used when appropriate. Survival analysis was performed only in patients with invasive carcinoma. For statistical analyses, BRAF V600E mutation status was defined as follows: Cases with unequivocal V600E mutant protein expression were regarded as "BRAF V600E positive," also in cases in which genetic analysis was inconclusive. Cases with no or equivocal VE1 immunostaining result and without gene mutation were considered as "BRAF V600E negative." Overall survival (OS) was defined from the day of primary surgery until cancer death of the patient. Deaths from other cause than ovarian carcinoma or survival until the end of the observation period were considered as censored observations. Disease-free survival (DFS) was defined from the end of primary therapy until first evidence of progression of disease. Patients with progressive disease under primary chemotherapy were excluded from analysis of DFS.
Log-rank test was used for univariate analysis of survival. A 2-tailed P value of r0.05 was considered as significant
RESULTS
BRAF V600E Status
We found cytoplasmic anti-BRAF V600E immunolabeling of tumor cells in 4 serous carcinomas (3 low grade, 1 high grade) and 5 serous LMP ( Fig. 1 ). No staining of ovarian superficial epithelial cells or cells of the epithelium of the fallopian tube (if present) was seen in any case. In 4 of these cases, genetic analysis confirmed the presence of a BRAF V600E mutation and in 1 no evaluable DNA sequence could be generated. In 2 LMP cases with low tumor cell content, genetic analysis initially showed BRAF wild-type, but a second genetic analysis of macrodissected tumor cells lead to the identification of BRAF V600E mutations in both cases (Fig. 1C and D) . Two tumors deriving from the same patient (1 LMP and 1 contralateral invasive high-grade serous carcinoma) showed heterogenous VE1 immunostaining of weak to moderate intensity (Fig. 1E ). In both of these paraffin blocks genetic analysis showed BRAF wild-type in 3 independent runs (2 were done in Vienna and 1 in Heidelberg), arguing for false-positive immunostaining results. In all genetically confirmed cases, BRAF V600E mutant protein expression was homogenous throughout the tumor tissue. In 6 cases of serous invasive ovarian carcinoma with negative VE1 immunostaining result, genetic analysis confirmed BRAF wild-type. Table 1 shows the correlation of immunohistochemical and gene sequencing results and the correlation of BRAF V600E status with clinical parameters is shown in Table 2 .
Cell Cycle-related and Hypoxia-related Proteins and Vascularization
The frequency of expression of bcl-2, HIF-1a, p21, p53 in invasive carcinomas and LMP is shown in Table 3 . Mean MVD was 24 ± 17 (SD) microvessels/field.
Statistical Analyses
Although V600E mutations were only found in serous tumors, significance was missed when comparing frequency of V600E positivity in serous versus all other histologic subtypes (P = 0.096, Fisher exact test). No significant difference in V600E status was seen when comparing LMP versus invasive tumors, also when analyzing only serous tumors (P > 0.05, respectively, w 2 tests).
In the subpopulation of invasive carcinoma patients, we observed a significant difference in FIGO stage between VE1 positive and negative cases (P = 0.035, Mann-Whitney test): whereas in VE1-negative cases the median FIGO stage was IIIB, it was IA in positive cases. We found no association of V600E status with patients' age, MVD, HIF-1a or p53 expression in this cohort (P > 0.05, Mann-Whitney test or w 2 test, respectively). In serous ovarian carcinomas, V600E positivity was significantly more common in low grade compared with high-grade tumors (P = 0.022, Fisher exact test, Table 2 ).
There was a significant positive correlation of BRAF V600E expression with p21 expression in the entire cohort and in the subpopulation of LMP tumors, respectively. In both groups, median p21 expression score was "absent" in V600E-negative and "moderate" in V600E-positive tumors (P = 0.008 and 0.019, respectively, Mann-Whitney test).
When analyzing LMP and invasive carcinomas together, we observed a negative correlation of BRAF V600E status with bcl-2 expression (P = 0.048, Mann-Whitney test): Median BCL-2 score was "weak" in V600E-negative and "absent" in V600E-positive cases.
Survival Analysis
In patients with invasive carcinoma, the mean observation time was 37.4 ± 9.1 months. During this time period, 25 developed recurrent disease and 39 patients (39.8%) died from their carcinoma. A strong trend toward better DFS and OS in carcinomas with BRAF wild-type status was seen, which did not reach statistical significance (DFS: 0.304; OS: P = 0.218, log rank test; Fig. 2 ).
DISCUSSION
According to the dualistic model of ovarian carcinogenesis, ovarian carcinomas are divided into 2 broad categories (type I and II neoplasms) that form through distinct pathogenic pathways. 14 15 In agreement with this model and with previous genetic studies BRAF V600E mutation was exclusive to serous LMP and serous carcinoma and we observed a significant association of BRAF V600E status with low FIGO stage in invasive carcinomas. [5] [6] [7] [8] BRAF inhibitors are emerging as novel and effective anticancer drugs. Vemurafenib was approved for the treatment of metastatic melanoma with BRAF V600E mutations and clinical trials with other BRAF inhibitors and in other patient populations are underway. 3, 4 BRAF inhibitors may also be effective in some ovarian tumors, as drug-induced inactivation of the MAPK has been shown to induce growth inhibition and apoptosis in serous ovarian tumors harboring BRAF V600E mutations. 16 We show in the present study that BRAF V600E mutant protein is generally expressed homogenously throughout the tumor tissue in mutated cases, thus making it an attractive target for systemic targeted drugs. Such a therapeutic approach could be particularly interesting for low-grade serous carcinomas that have been shown to have lower response rates to conventional chemotherapy than high-grade serous carcinomas. 17 Of note, we found the BRAF V600E mutation in one of 15 cases of brain-metastatic serous ovarian carcinoma in a previous study. 10 Our findings have general implications for clinical BRAF V600E testing. Obviously, correct identification of mutated and nonmutated cases is of paramount importance to avoid patient mistreatment with or without BRAF inhibitors. So far, testing of the BRAF status is performed using various DNA-based methods and a realtime polymerase chain reaction based assay to detect BRAF V600E mutations was FDA-approved for patient selection for vemurafenib therapy. Our data suggest that an integrated approach using anti-BRAF V600E Â400) . B, Negative VE1 immunostaining result in a case of serous ovarian carcinoma with BRAF wild-type (original magnification Â200). C and D, In this case of LMP, VE1 immunostaining labeled tumor cells embedded in large areas of non-neoplastic tissue (C, original magnification Â 25). Genetic analysis initially showed BRAF wild-type, but a second genetic analysis of macrodissected tumor (D, original magnification Â400) lead to the identification of a BRAF V600E mutation. E, This serous ovarian carcinoma showed heterogenous VE1 immunostaining of weak to moderate intensity (original magnification Â 200). Genetic analysis repeatedly showed BRAF wild-type.
immunostaining in addition to a DNA-based method may increase the diagnostic accuracy, as none of the techniques has perfect analytical performance. DNAbased analysis may incorrectly indicate BRAF wild-type (false-negative results) in samples with high content of non-neoplastic DNA such as cases with small tumor cell formations embedded in surrounding tissue parts. Separation of tumor cells from surrounding tissues by macrodissection or microdissection may increase the accuracy of DNA-based testing, but this is currently not feasible in the routine clinical setting. Another problem is that impaired DNA quality due to tissue processing (FFPE) or mixture with necrotic tissue may lead to noninterpretable results of DNA-based analysis. We show that in at least a proportion of cases with false-negative or inconclusive gene sequencing results, VE1 immunostaining is able to label BRAF V600E-expressing tumor cells. Therefore, anti-BRAF V600E immunohistochemistry may allow identification of patients eligible for BRAF-inhibiting therapies that would have been missed based on DNAbased analysis alone. In contrast, interpretation of VE1 immunostaining has also some caveats. First, VE1 immunostaining is not able to identify rare non-V600E mutations including the BRAF V600K mutation, which seems to also confer sensitivity to BRAF-inhibiting drugs.
In our present study we show that in single cases VE1 may produce an unspecific immunostaining reaction, possibly leading to false-positive results. In contrast to the cases with confirmed BRAF V600E mutation at the genetic level, the immuno-positive cases with wild-type BRAF showed an inhomogenous staining reaction, which may help to identify false-positive cases. In addition, as discussed previously focal weak or absent VE1 immunostaining in otherwise immunoreactive tumor tissue samples may be observed in areas of beginning necrosis (prenecrosis) and in relation to artificial tissue damage. 9 It is important to note that sections have to be freshly cut from FFPE blocks for optimal VE1 immunostaining results, as we observed marked decrease of VE1 immunostaining intensity in tissue sections stored for longer than a few weeks. 9, 10 Interestingly, we found a significant positive correlation of BRAF V600E expression with expression of p21 and an inverse correlation of BRAF V600E expression with bcl-2 expression. It must be noted, however, that the *All these cases showed homogenous VE1 immunostaining throughout the tumor tissue. In 2 of these 6 cases, genetic analysis initially showed BRAF wild-type, but a second genetic analysis of macrodissected tumor cells lead to the identification of BRAF V600E mutations in both cases.
wThese cases showed inhomogenous VE1 immunostaining and repeated gene sequencing showed BRAF wild-type. power of our statistical correlations is very limited by the small number of V600E mutated ovarian tumors. Still, in line with our findings high p21 promoter activity and expression in response to BRAF V600E signaling by MEK and ROS-dependent phosphorylation of FOXO4 has been identified in melanoma cells. 18 This cascade has been proposed to participate in the regulation of oncogene-induced senescence response. Our data may suggest a potential role of this mechanism in the pathogenesis of BRAF V600E-mutated ovarian tumors. Further studies are needed to clarify the role of the cell cycle-associated protein p21 and bcl-2 in their interaction with BRAF in ovarian tumors. 
